<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339885</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091409</ELocationID><Abstract><AbstractText>Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (<i>n</i> = 60) and Vaccinated + Previously Infected (<i>n</i> = 60). A commercial sVNT, the ACE2-RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups (<i>p</i> &lt; 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cin</LastName><ForeName>Dilan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9783-8616</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Sciences, Istanbul University, 34126 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soguksu</LastName><ForeName>Pinar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oren</LastName><ForeName>Meryem Merve</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-3383-7830</Identifier><AffiliationInfo><Affiliation>Department of Public Health, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozgulnar</LastName><ForeName>Nuray</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1948-4194</Identifier><AffiliationInfo><Affiliation>Department of Public Health, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agacfidan</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mese</LastName><ForeName>Sevim</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5944-0180</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TYL-2022-38565.</GrantID><Agency>Istanbul University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="Y">Neutralization Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 IgG</Keyword><Keyword MajorTopicYN="N">chemiluminescent microparticle immunoassay (CMIA)</Keyword><Keyword MajorTopicYN="N">surrogate virus neutralization test (sVNT)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339885</ArticleId><ArticleId IdType="pmc">PMC11437471</ArticleId><ArticleId IdType="doi">10.3390/v16091409</ArticleId><ArticleId IdType="pii">v16091409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Post N., Eddy D., Huntley C., van Schalkwyk M.C.I., Shrotri M., Leeman D., Rigby S., Williams S.V., Bermingham W.H., Kellam P., et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE. 2020;15:e0244126. doi: 10.1371/journal.pone.0244126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244126</ArticleId><ArticleId IdType="pmc">PMC7775097</ArticleId><ArticleId IdType="pubmed">33382764</ArticleId></ArticleIdList></Reference><Reference><Citation>Winichakoon P., Wipasa J., Chawansuntati K., Salee P., Sudjaritruk T., Yasri S., Khamwan C., Peerakam R., Dankai D., Chaiwarith R. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT) Sci. Rep. 2023;13:34. doi: 10.1038/s41598-022-26202-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-26202-1</ArticleId><ArticleId IdType="pmc">PMC9806819</ArticleId><ArticleId IdType="pubmed">36593231</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton D.R., Williamson R.A., Parren P.W. Antibody and Virus: Binding and Neutralization. Virology. 2000;270:1–3. doi: 10.1006/viro.2000.0239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0239</ArticleId><ArticleId IdType="pubmed">10772973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavlek T.V., Stevanovic V., Kovac S., Borko E., Bogdanic M., Miletic G., Hruskar Z., Ferenc T., Coric I., Ferenc M.V., et al. Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals. Antibodies. 2023;12:61. doi: 10.3390/antib12040061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib12040061</ArticleId><ArticleId IdType="pmc">PMC10594469</ArticleId><ArticleId IdType="pubmed">37873858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chvatal-Medina M., Mendez-Cortina Y., Patino P.J., Velilla P.A., Rugeles M.T. Antibody Responses in COVID-19: A Review. Front. Immunol. 2021;12:633184. doi: 10.3389/fimmu.2021.633184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.633184</ArticleId><ArticleId IdType="pmc">PMC8081880</ArticleId><ArticleId IdType="pubmed">33936045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcurumez M.K., Ambrosch A., Frey O., Haselmann V., Holdenrieder S., Kiehntopf M., Neumaier M., Walter M., Wenzel F., Wolfel R., et al. SARS-CoV-2 Antibody Testing—Questions to be Asked. Allergy Clin. Immunol. 2020;146:35–43. doi: 10.1016/j.jaci.2020.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7256507</ArticleId><ArticleId IdType="pubmed">32479758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru Z., Zhang Y., Wu J., Huang H., Liang Y., Yang X., Wu J., Lou J. Comparison of the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Assay and Direct Binding ELISA (S-IgG) with the Cytopathic Effect Assay (CPE) in Analyzing the Neutralization Antibody of Vaccination People. J. Clin. Immunol. Immunother. 2021;7:063. doi: 10.24966/CIIT-8844/1000063.</Citation><ArticleIdList><ArticleId IdType="doi">10.24966/CIIT-8844/1000063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Ruben O.D., Koup R.A., Fong Y., Plotkin S.A., Folmen D. A COVID-19 Milestone Attained-A Correlate of Protection for Vaccines. N. Engl. J. Med. 2022;387:2203–2206. doi: 10.1056/NEJMp2211314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Galipeau Y., Greig M., Liu G., Driedger M., Langlois M.A. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front. Immunol. 2020;11:610688. doi: 10.3389/fimmu.2020.610688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.610688</ArticleId><ArticleId IdType="pmc">PMC7775512</ArticleId><ArticleId IdType="pubmed">33391281</ArticleId></ArticleIdList></Reference><Reference><Citation>Riepler L., Rössler A., Falch A., Volland A., Borena W., von Laer D., Kimpel J. Comparison of Four SARS-CoV-2 Neutralization Assays. Vaccines. 2020;9:13. doi: 10.3390/vaccines9010013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9010013</ArticleId><ArticleId IdType="pmc">PMC7824240</ArticleId><ArticleId IdType="pubmed">33379160</ArticleId></ArticleIdList></Reference><Reference><Citation>Souiri A., Lemriss S., El Maliki B., Falahi H., El-Fahime E., El-Kabbaj S. SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization. Vaccines. 2023;11:590. doi: 10.3390/vaccines11030590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030590</ArticleId><ArticleId IdType="pmc">PMC10054367</ArticleId><ArticleId IdType="pubmed">36992173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohmer N., Westhaus S., Rühl C., Ciesek S., Rabenau H.F. Clinical performance of different SARS-CoV-2 IgG antibody tests. J. Med. Virol. 2020;92:2243–2247. doi: 10.1002/jmv.26145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26145</ArticleId><ArticleId IdType="pmc">PMC7300776</ArticleId><ArticleId IdType="pubmed">32510168</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan L., Mao Q., Tan D., Liu J., Zhang X., Li L., Liu M., Wang Z., Cheng F., Cui B., et al. Establishment of national standard for anti-SARS-CoV-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard. Front. Immunol. 2023;14:1107639. doi: 10.3389/fimmu.2023.1107639.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1107639</ArticleId><ArticleId IdType="pmc">PMC9971588</ArticleId><ArticleId IdType="pubmed">36865542</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.T., Han Y.J., Wu G.H., Huang K.Y.A., Huang P.N. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses. 2022;14:1560. doi: 10.3390/v14071560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071560</ArticleId><ArticleId IdType="pmc">PMC9322699</ArticleId><ArticleId IdType="pubmed">35891540</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K.T., Li Z., Samson R., Samavarchi-Tehrani P., Valcourt E.J., Wood H., Wood H., Budylowskiet P., Il D.A.P., Girardin R.C., et al. A Simple Protein-Based Surrogate Neutralization Assay for SARS-CoV-2. JCI Insight. 2020;5:e142362. doi: 10.1172/jci.insight.142362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142362</ArticleId><ArticleId IdType="pmc">PMC7566699</ArticleId><ArticleId IdType="pubmed">32870820</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer B., Reimerink J., Torriani G., Brouwer F., Godeke G.J., Yerly S., Hoogerwerf M., Vuilleumier N., Kaiser L., Eckerle I., et al. Validation and Clinical Evaluation of a SARS-CoV-2 Surrogate Virus Neutralisation Test (sVNT) Emerg. Microbes Infect. 2020;9:2394–2403. doi: 10.1080/22221751.2020.1835448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1835448</ArticleId><ArticleId IdType="pmc">PMC7605318</ArticleId><ArticleId IdType="pubmed">33043818</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Klett J., Gabert J., Lipp T., Karbach J., Jäger E., Borte S., Hoffmann R., Milkovska-Stamenova S. A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals. Microorganisms. 2022;10:1812. doi: 10.3390/microorganisms10091812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10091812</ArticleId><ArticleId IdType="pmc">PMC9502828</ArticleId><ArticleId IdType="pubmed">36144414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Sasso B., Agnello L., Giglio R.V., Gambino C.M., Ciaccio A.M., Vidali M., Ciaccio M. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine. Sci. Rep. 2022;12:8679. doi: 10.1038/s41598-022-12750-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12750-z</ArticleId><ArticleId IdType="pmc">PMC9126106</ArticleId><ArticleId IdType="pubmed">35606426</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos da Silva E., Servais J.-Y., Kohnen M., Arendt V., Staub T., the CON-VINCE Consortium. the CoVaLux Consortium. Krüger R., Fagherazzi G., Wilmes P., et al. Validation of a SARS-CoV-2 Surrogate Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern. Int. J. Mol. Sci. 2023;24:14965. doi: 10.3390/ijms241914965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241914965</ArticleId><ArticleId IdType="pmc">PMC10573711</ArticleId><ArticleId IdType="pubmed">37834413</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J., Gillot C., Di Chiaro L., Eucher C., Elsen M., Van Eeckhoudt S., David C., Morimont L., Dogné J.-M., Douxfils J. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses. 2021;13:1364. doi: 10.3390/v13071364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071364</ArticleId><ArticleId IdType="pmc">PMC8309994</ArticleId><ArticleId IdType="pubmed">34372570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I.C., Tiu C., Hu Z., Chen V.C.-V., Young B.E., Wan R.S., et al. A SARS-CoV-2 Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2–Spike Protein–Protein Interaction. Nat. Biotechnol. 2020;38:1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolscheid-Pommerich R., Bartok E., Renn M., Kümmerer B.M., Schulte B., Schmithausen R.M., Stoffel-Wagner B., Streeck H., Saschenbrecker S., Steinhagen K., et al. Correlation Between a Quantitative Anti-SARS-CoV-2 IgG ELISA and Neutralization Activity. J. Med. Virol. 2022;94:388–392. doi: 10.1002/jmv.27287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27287</ArticleId><ArticleId IdType="pmc">PMC8426838</ArticleId><ArticleId IdType="pubmed">34415572</ArticleId></ArticleIdList></Reference><Reference><Citation>Malipiero G., D’Agaro P., Segat L., Moratto A., Villalta D. Long-Term Decay of Anti-RBD IgG Titers after BNT162b2 Vaccination is not Mirrored by Loss of Neutralizing Bioactivity Against SARS-CoV-2. Clin. Chim. Acta. 2022;524:11–17. doi: 10.1016/j.cca.2021.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.11.023</ArticleId><ArticleId IdType="pmc">PMC8630423</ArticleId><ArticleId IdType="pubmed">34843705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G., Zhao Q. Perspectives on Therapeutic Neutralizing Antibodies Against the Novel Coronavirus SARS-CoV-2. Int. J. Biol. Sci. 2020;16:1718–1723. doi: 10.7150/ijbs.45123.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.45123</ArticleId><ArticleId IdType="pmc">PMC7098029</ArticleId><ArticleId IdType="pubmed">32226289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokida D., Karyana M., Kosasih H., Mardian Y., Sugiyono R.I., Arlinda D., Lukman N., Salim G., Butar D.P.B., Naysilla A.M., et al. Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies. Heliyon. 2022;8:e12614. doi: 10.1016/j.heliyon.2022.e12614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e12614</ArticleId><ArticleId IdType="pmc">PMC9783098</ArticleId><ArticleId IdType="pubmed">36575657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli F., Sarasini A., Zierold C., Calleri M., Bonetti A., Vismara C., Blocki F.A., Pallavicini L., Chinali A., Campisi D., et al. Clinical and Analytical Performance of An Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J. Clin. Microbiol. 2020;58:e01224-20. doi: 10.1128/JCM.01224-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01224-20</ArticleId><ArticleId IdType="pmc">PMC7448652</ArticleId><ArticleId IdType="pubmed">32580948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Q.L., Zhang Y.C., Lian L.J., Qu Y.Y., Wu W., Chen Z., Pei R.J., Chen T.Y., Sun L.N., Li C., et al. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. Viruses. 2021;13:1508. doi: 10.3390/v13081508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081508</ArticleId><ArticleId IdType="pmc">PMC8402865</ArticleId><ArticleId IdType="pubmed">34452373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger J.E., Fert-Bober J., Printsev I., Wu M., Sun N., Prostko J.C., Frias E.C., Stewart J.L., Van Eyk J.E., Braun J.G., et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 2021;27:981–984. doi: 10.1038/s41591-021-01325-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01325-6</ArticleId><ArticleId IdType="pmc">PMC8205849</ArticleId><ArticleId IdType="pubmed">33795870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouna L., Razazian M., Duquesne S., Roque-Afonso A.M., Vauloup-Fellous C. Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. Viruses. 2023;15:426. doi: 10.3390/v15020426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020426</ArticleId><ArticleId IdType="pmc">PMC9958856</ArticleId><ArticleId IdType="pubmed">36851641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagawa Y., Imai K., Matsuoka M., Fukada A., Kubota K., Sato M., Takada T., Noguchi S., Tarumoto N., Maesakiet S., et al. Evaluation of the Correlation between the Access SARS-CoV-2 IgM and IgG II Antibody Tests with the SARS-CoV-2 Surrogate Virus Neutralization Test. J. Med. Virol. 2022;94:335–341. doi: 10.1002/jmv.27338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27338</ArticleId><ArticleId IdType="pmc">PMC8661952</ArticleId><ArticleId IdType="pubmed">34524695</ArticleId></ArticleIdList></Reference><Reference><Citation>Infantino M., Manfredi M., Stacchini L., Cosma C., Grossi V., Lari B., Russo E., Amedei A., Benucci M., Veneziani F., et al. The Role of Neutralizing Antibodies by sVNT after Two Doses of BNT162b2 mRNA Vaccine in a Cohort of Italian Healthcare Workers. Clin. Chem. Lab. Med. 2022;60:934–940. doi: 10.1515/cclm-2022-0170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2022-0170</ArticleId><ArticleId IdType="pubmed">35303766</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Stegmaier R., Cereceda K., Briones J., Beltran-Pávez C., Oyarzún-Arrau A., Riquelme-Barrios S., Selman C., Yarad F., Mahave M., Caglevic C., et al. Seroconversion and Abundance of IgG Antibodies Against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean population. J. Immunol. Res. 2021;19:6680337. doi: 10.1155/2021/6680337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6680337</ArticleId><ArticleId IdType="pmc">PMC7901042</ArticleId><ArticleId IdType="pubmed">33644235</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Du L. SARS-CoV-2 spike protein: A key target for eliciting persistent neutralizing antibodies. Signal Transduct. Target. Ther. 2021;6:95. doi: 10.1038/s41392-021-00523-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00523-5</ArticleId><ArticleId IdType="pmc">PMC7908000</ArticleId><ArticleId IdType="pubmed">33637679</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.H., Porrot F., Staropoli I., Père H., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Faraone J., Evans J.P., Zou X., Zheng Y.M., Carlin C., Bednash J.S., Lozanski G., Mallampalli R.K., Saif L.J., et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N. Engl. J. Med. 2022;386:2526–2528. doi: 10.1056/NEJMc2206725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206725</ArticleId><ArticleId IdType="pmc">PMC9258774</ArticleId><ArticleId IdType="pubmed">35704428</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño J.M., Alshammary H., Tcheou J., Singh G., Raskin A.J., Kawabata H., Sominsky L.A., Clark J.J., Adelsberg D.C., Bielak D.A., et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602:682–688. doi: 10.1038/s41586-022-04399-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04399-5</ArticleId><ArticleId IdType="pubmed">35016197</ArticleId></ArticleIdList></Reference><Reference><Citation>Higdon M.M., Baidya A., Walter K.K., Patel M.K., Issa H., Espie E., Feikin D.R., Knoll M.D. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect. Dis. 2022;22:1114–1116. doi: 10.1016/S1473-3099(22)00409-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00409-1</ArticleId><ArticleId IdType="pmc">PMC9221361</ArticleId><ArticleId IdType="pubmed">35752196</ArticleId></ArticleIdList></Reference><Reference><Citation>Michlmayr D., Hansen C.H., Gubbels S.M., Valentiner-Branth P., Bager P., Obel N., Drewes B., Møller C.H., Møller F.T., Legarth R., et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg. Health Eur. 2022;20:100452. doi: 10.1016/j.lanepe.2022.100452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100452</ArticleId><ArticleId IdType="pmc">PMC9245510</ArticleId><ArticleId IdType="pubmed">35791335</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Initiative on Sharing All Influenza Data (GISAID); hCoV-19 Variants Dashboard.  [(accessed on 17 July 2024)].  Available online:  https://gisaid.org/hcov-19-variants-dashboard/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>